Feasibility study of the bi-weekly administration of eribulin for metastatic breast cancer

Feasibility study of the bi-weekly administration of eribulin for metastatic breast cancer - Feasibility study of the bi-weekly administration of eribulin for metastatic breast cancer

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013596

Enrollment

Registered

2014-04-01

Start date

2014-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic breast cancer

Interventions

Eribulin

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: (1)The women histologically diagnosed as breast cancer (2) The patients who received previous chemotherapy with anthracycline and taxane (3)Age 20&#8211;75 years (4)ECOG PS: 0-2 (5)The patients with the measurable lesion by RECIST version 1.1 (6)The patients with adequate organ function (7)Written informed consent was obtained from each patient prior to enrollment.

Exclusion criteria

Exclusion criteria: Patients with serious complications, a history of drug hypersensitivity, brain metastases with any symptoms, active secondary cancer, or pregnant women were excluded.

Design outcomes

Primary

Measure	Time frame
ORR, overall response rate	—

Countries

Japan

Contacts

Public ContactTakashi Shigekawa

Saitama Medical University International Medical Center Department of Breast Oncology

takshige@saitama-med.ac.jp+81-42-984-4670

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026